DORAL, Florida, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today announces successful in vitro analyses of gynecological samples collected using its new Hygee™ medical device.
Hygee™ is a discreet, wearable medical device that enables a woman to anonymously test for sexually transmitted infections (STIs). As previously announced, samples collected by the Hygee™ device are tested by Procréa. In pre-launch testing at the labs, molecular diagnostic assays successfully identified the presence of Chlamydia in test subjects, confirming earlier testing results in a cohort of more than 500 women.
ETST’s President, Director and Chairman Nickolas S. Tabraue states, “We are pleased to announce positive testing in the pre-launch phase of Hygeeâ„¢, and would like to thank our carefully selected partners, Procréa, for a job well done. They are a part of the guarantee of our success.â€
ETST is on track to launch Hygee™ in early 2019. The Company plans to market the product through its established distribution channels, mentioned in November, thanks to Dermagate’s ISO 13485:2013 certification.
“Hygeeâ„¢ is an incredible innovation, and we have partners from many countries waiting to market the device,†stated ETST CEO and Chief Scientific Officer Dr. Michel Aubé. “This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.â€
In its first iteration, Hygeeâ„¢ will be marketed as an at-home test for chlamydia; however, R&D efforts currently underway indicate that Hygeeâ„¢ will soon be certified for gonorrhea testing as well.
About Earth Science Tech, Inc.
(ETST)
Earth Science Tech, Inc. (“ETSTâ€) offers the highest purity and
quality high-grade full spectrum cannabinoid oil on the market.
There are positive results in studies on breast cancer and immune
cells through the University of Central Oklahoma, in addition to
studies through DV Biologics that prove the Company’s CBD oil
formulation lowers cortisol and functions as a neuro-protectant,
with positive result case studies through key health organizations.
ETST formulates, markets and distributes the CBD oil used for its
studies to the public, offering the most effective quality of CBD
on the market.
To learn more, please visit: www.EarthScienceTech.com
ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors:
Earth Science Pharmaceutical,
Inc.
Earth Science Pharmaceutical ("ESP") is a wholly-owned subsidiary
of Earth Science Tech, committed to the development of low cost,
non-invasive diagnostic tools, medical devices, testing processes
and vaccines for sexually transmitted infections and/or diseases.
ESP's CEO and chief science officer, Dr. Michel Aubé, is
leading the Company’s research and development efforts. The
Company’s first medical device, Hygee™, is a home kit designed for
the detection of STIs, such as chlamydia, from a self-obtained
gynecological specimen. ESP is working to develop and bring to
market medical devices and vaccines that meet the specific needs of
women. To learn more please visit: www.EarthSciencePharmaceutical.com
Cannabis Therapeutics,
Inc.
Cannabis Therapeutics (“CTIâ€) is a wholly-owned subsidiary of Earth
Science Tech, Inc. poised to take a leadership role in the
development of new, leading-edge cannabinoid-based pharmaceutical
and nutraceutical products. CTI is invested in research and
development to explore and harness the medicinal power of
cannabidiol. The company holds three provisional application
patents for a CBD product that is focused on developing treatments
for breast and ovarian cancers, as well as two generic CBD based
pharmaceutical drugs. To learn more please visit: www.CannabisThera.com
KannaBidioiD, Inc.
KannaBidioiD (“KBDâ€) is a wholly-owned subsidiary of Earth Science
Tech, Inc. that provides a wide variety of products geared toward
the recreational space of cannabis. KBD’s unique Kanna and CBD
formulation is sold and distributed in CBD-infused vapes/e-liquids
products. Kanna and CBD synergistically enhance one another,
providing optimal relaxation, an uplifting sensation, enhanced
focus and the added benefit of assisting with nicotine reduction
therapy. To learn more please visit: www.KannaBidioiDInc.com
Earth Science Foundation,
Inc.
Earth Science Foundation (“ESFâ€) is a wholly-owned subsidiary of
Earth Science Tech, Inc. ESF is in the process of becoming a
non-profit organization to accept grants and donations to conduct
further studies and help donate Earth Science Tech's effective CBD
products to those in need. To learn more please visit:
www.ETSTFoundtion.org
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, listing on the CSE, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
www.EarthScienceTech.com
Nickolas S. Tabraue
President, Director & Chairman
305.615.2118 Office
Corporate Communications
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]